

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 October 2022 (27.10.2022)



(10) International Publication Number
WO 2022/224187 A1

(51) International Patent Classification:

A61K 31/00 (2006.01) C07K 16/28 (2006.01)
A61K 33/00 (2006.01) C12N 9/26 (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:

PCT/IB2022/053733

(22) International Filing Date:

21 April 2022 (21.04.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/177,518 21 April 2021 (21.04.2021) US
63/180,690 28 April 2021 (28.04.2021) US
63/309,230 11 February 2022 (11.02.2022) US

(71) Applicant: JANSSEN BIOTECH, INC. [US/US];
800/850 Ridgeview Drive, Horsham, Pennsylvania 19044
(US).


(72) Inventors: KNOBLAUCH, Roland; 1400 McKean Road,
Spring House, Pennsylvania 19477 (US). TORNE, Satyen;
200 Great Valley Parkway, Malvern, Pennsylvania 19355
(US).

(74) Agent: SHIRTZ, Joseph F. et al.; JOHNSON &
JOHNSON, One Johnson & Johnson Plaza, New
Brunswick, New Jersey 08933 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: HIGH CONCENTRATION BISPECIFIC ANTIBODY FORMULATIONS



(57) Abstract: Provided herein are stable aqueous pharmaceutical compositions comprising high concentration formulations of a bispecific epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody and methods of preparing the same. Also provided herein are methods of treating cancer in a subject in need thereof by subcutaneously administering to the subject the stable aqueous pharmaceutical compositions as disclosed herein.

[Continued on next page]

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*